PACBPacific Biosciences of California, Inc.
$2.30+64% 1Y
$2.30
$1.1152 weeks$2.88
PACB in its own filings
Nothing in PACB's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
300
Events found in the filings · across 970 filings · the record starts in 2010
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 6, 2026
Most recent filing · Form 10-Q
- Record starts
- Sep 10, 2010
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 4, 2026
- Change in certifying accountanthistorical
- 2011-06-21
- SEC comment-letter activity17 occurrences
- 2021-06-03
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 5, 2026On July 30, 2026, the Board of Directors (the “Board”) of the Company approved a restructuring plan to continue to better align the Company’s organizational structure and resources with its strategic initiatives.Earnings release · Form 8-K
- Jul 9, 2026On July 8, 2026, Christopher M. Smith, a member of the board of directors (the “Board”) of Pacific Biosciences of California, Inc. (the “Company”), notified the Company of his resignation from the Board, effective immediately.Director or officer change · Form 8-K
- Jun 4, 2026On April 21, 2026, the board of directors (the "Board") of Pacific Biosciences of California, Inc. (the “Company”), at the recommendation of the compensation committee of the Board, approved an amendment (the “Amendment”) to the Company’s 2020 Equity Incentive Plan (the “2020 Plan”), subject to stockholder approval …Director or officer change · Form 8-K
- May 7, 2026PacBio Announces First Quarter 2026 Financial Results.Earnings release · press release
- Mar 6, 2026On March 2, 2026, Michele Farmer notified Pacific Biosciences of California, Inc. (the "Company") that she is voluntarily resigning as Chief Accounting Officer of the Company effective on March 21, 2026, to pursue another opportunity.Director or officer change · Form 8-K
- Mar 5, 2026On March 3, 2026 (the “Effective Date”), the Board of Directors (the “Board”) of Pacific Biosciences of California, Inc. (the “Company”), upon the recommendation of its Corporate Governance and Nominating Committee, increased the size of the Board to ten directors and appointed Christopher Gibson, Ph.D. to serve as a …Director or officer change · Form 8-K
- Feb 12, 2026PacBio Announces Fourth Quarter and Full Year 2025 Financial Results.Earnings release · press release
- Feb 3, 2026On February 3, 2026, Pacific Biosciences of California, Inc. (the “Company”) announced that, effective January 28, 2026, Mark Van Oene, the Company’s Chief Operating Officer, will on an interim basis assume responsibilities for the Company’s sales and customer support organizations, which were previously assigned to …Director or officer change · Form 8-K
- Feb 2, 2026The information regarding the Asset Purchase Agreement (as defined below) set forth in.Material agreement entered · Form 8-K
- Nov 5, 2025PacBio Announces Third Quarter 2025 Financial Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…